Physician profile
Michael Kent
NPI 1174607071
$3,861.26
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,895 · 2020: $408 · 2021: $193 · 2022: $817 · 2023: $176 · 2024: $373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $549.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $549.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $676.00 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $651.97 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $564.62 | 2019-2024 | Abilify Maintena, Abilify Asimtufii |
| Supernus Pharmaceuticals, INC. | $475.28 | 2021-2023 | Qelbree |
| Janssen Pharmaceuticals, INC | $299.15 | 2019-2023 | Invega Sustenna |
| Vanda Pharmaceuticals INC. | $257.96 | 2019-2024 | Fanapt |
| Neurocrine Biosciences, INC. | $162.40 | 2019-2022 | |
| Allergan, INC. | $160.78 | 2019-2020 | |
| Alkermes, INC. | $130.82 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $126.24 | 2024 | |
| Neos Therapeutics, Lp | $96.54 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $62.47 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $49.61 | 2019-2022 | |
| Lundbeck LLC | $31.96 | 2019-2023 | Rexulti |
| Corium, LLC | $22.51 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $18.51 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $18.40 | 2021 | |
| Noven Therapeutics, LLC | $15.24 | 2022 | |
| Acadia Pharmaceuticals INC | $15.22 | 2019 | |
| Merck Sharp & Dohme LLC | $14.59 | 2022 | |
| Rhodes Pharmaceuticals L.P. | $10.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.